Karl-Peter Hopfner

Title: Karl-Peter Hopfner: Innovator in Myeloid Targeting Therapies

Introduction

Karl-Peter Hopfner is a distinguished inventor based in Berg, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of innovative therapies targeting myeloid cells. With a total of three patents to his name, his work is paving the way for advancements in cancer treatment.

Latest Patents

Among his latest patents is the invention of a CD33-, CD16-, and CD123-specific single chain triplebody. This invention relates to a nucleic acid molecule that encodes a chain myeloid capable of specifically binding to CD33, CD16, and CD123. The patent outlines various components of the nucleic acid molecule, including sequences that can be used for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Another notable patent is for a trispecific molecule that combines specific tumor targeting with local immune checkpoint inhibition. This novel molecule features three binding sites, enhancing its potential as a pharmaceutical composition for cancer therapies.

Career Highlights

Karl-Peter Hopfner has worked with prestigious institutions, including Ludwig Maximilians University Munich and Helmholtz Zentrum München, which is part of the German Research Center for Environmental Health. His work in these organizations has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Some of his notable coworkers include Nadja Fenn and Daniel Krappmann. Their collaborative efforts have further advanced the research and development of innovative therapeutic solutions.

Conclusion

Karl-Peter Hopfner's contributions to biotechnology and cancer treatment through his patents and collaborations highlight his role as a key innovator in the field. His work continues to inspire advancements in medical therapies aimed at improving patient outcomes.